GlassScriptPhysician profile
Edie E Zusman
NPI 1629178637
$460.98
in general payments reported to CMS, 2019-2025
14 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $72.51 · 2022: $122.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Nevro Corp. | $88.36 | 2019-2020 | |
| Avanir Pharmaceuticals, INC. | $65.96 | 2019-2022 | |
| Amgen INC. | $44.67 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $44.07 | 2022 | |
| Neuropace, INC. | $38.23 | 2019 | |
| Genzyme Corporation | $30.38 | 2019 | |
| Varian Medical Systems, INC. | $27.50 | 2020 | |
| Surgalign Spine Technologies, INC. | $19.65 | 2019 | |
| Vanda Pharmaceuticals INC. | $19.34 | 2022 | |
| Ge Healthcare | $19.03 | 2019 | |
| Lilly USA, LLC | $18.47 | 2022 | |
| Adamas Pharmaceuticals, INC. | $16.99 | 2019 | |
| Ucb, INC. | $15.17 | 2019 | |
| Electronic Waveform Lab, INC. | $13.16 | 2019 |
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Edie Zusman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.